ACROMEGALY: CURRENT MANAGEMENT AND THE EMERGING ROLE OF ORAL PALTUSOTINE
Abstract
Introduction and aim: Acromegaly is a chronic endocrine disorder caused by sustained excess secretion of growth hormone and insulin-like growth factor I, leading to significant morbidity and increased mortality if inadequately treated. Transsphenoidal surgery remains the primary therapeutic approach; however, a substantial proportion of patients fail to achieve durable biochemical remission and require long-term medical therapy. Injectable somatostatin receptor ligands are effective but are associated with treatment burden, variable biochemical responses, and impaired quality of life. The aim of this review was to summarize current management strategies for acromegaly and to evaluate the emerging role of paltusotine, a novel orally administered somatostatin receptor agonist.
Materials and Methods: This narrative review was based on a structured analysis of published clinical trials, extension studies, and review articles evaluating the pharmacological properties, clinical efficacy, and safety of paltusotine in patients with acromegaly.
Results: Available evidence indicates that paltusotine provides effective suppression of growth hormone secretion and reduction of insulin-like growth factor I levels with once-daily oral administration. Clinical studies demonstrate maintenance of biochemical control in patients previously treated with injectable therapies, as well as efficacy in selected untreated individuals. Paltusotine was generally well tolerated, with predominantly mild gastrointestinal adverse events and elimination of injection-related complications.
Conclusions: Paltusotine represents a promising oral alternative to injectable somatostatin receptor ligands, with the potential to reduce treatment burden, improve adherence, and maintain biochemical control. Further long-term and real-world studies are needed to fully define its role in routine clinical practice.
References
Ahmed, S., Asghar, H., & Khalid, M. (2025). A new era in oral treatment for acromegaly with the FDA-approved drug paltusotine. Annals of medicine and surgery (2012), 88(1), 1068–1069. https://doi.org/10.1097/MS9.0000000000004426
Badia, X., Webb, S. M., Prieto, L., & Lara, N. (2004). Acromegaly Quality of Life Questionnaire (AcroQoL). Health and quality of life outcomes, 2, 13. https://doi.org/10.1186/1477-7525-2-13
B M Biller, A Casagrande, A Elenkova, C L Boguszewski, R S Jallad, B Hu, E Hubina, P Fazeli, M Fleseriu, P J Snyder, C J Strasburger, M Bidlingmaier, M Buchfelder, P J Trainer, S Struthers, A Krasner, M Gadelha, 12535 Efficacy And Safety Of Once-daily Oral Paltusotine In Medically Untreated Patients With Acromegaly: Results From The Phase 3, Randomized, Placebo-controlled Pathfndr-2 Study, Journal of the Endocrine Society, Volume 8, Issue Supplement_1, October-November 2024, bvae163.1201, https://doi.org/10.1210/jendso/bvae163.1201
Chanson, P., & Salenave, S. (2008). Acromegaly. Orphanet journal of rare diseases, 3, 17. https://doi.org/10.1186/1750-1172-3-17
Colao, A., Grasso, L. F. S., Giustina, A., Melmed, S., Chanson, P., Pereira, A. M., & Pivonello, R. (2019). Acromegaly. Nature reviews. Disease primers, 5(1), 20. https://doi.org/10.1038/s41572-019-0071-6
Colao, A., Ferone, D., Marzullo, P., & Lombardi, G. (2004). Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine reviews, 25(1), 102–152. https://doi.org/10.1210/er.2002-0022
Colao, A., Auriemma, R. S., Pivonello, R., Kasuki, L., & Gadelha, M. R. (2016). Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary, 19(3), 235–247. https://doi.org/10.1007/s11102-015-0684-z
Fleseriu, M., Biller, B. M. K., Freda, P. U., Gadelha, M. R., Giustina, A., Katznelson, L., Molitch, M. E., Samson, S. L., Strasburger, C. J., van der Lely, A. J., & Melmed, S. (2021). A Pituitary Society update to acromegaly management guidelines. Pituitary, 24(1), 1–13. https://doi.org/10.1007/s11102-020-01091-7
Fleseriu, M., Molitch, M., Dreval, A., Biermasz, N. R., Gordon, M. B., Crosby, R. D., Ludlam, W. H., Haviv, A., Gilgun-Sherki, Y., & Mathias, S. D. (2021). Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands. Frontiers in endocrinology, 12, 627711.https://doi.org/10.3389/fendo.2021.627711
Gadelha, M. R., Gadelha, A. C., & Kasuki, L. (2024). New Treatments for Acromegaly in Development. The Journal of clinical endocrinology and metabolism, 109(4), e1323–e1327. https://doi.org/10.1210/clinem/dgad568
M Gadelha, H S Randeva, M B Gordon, M Doknic, E Mezosi, M Toth, C L Boguszewski, C Davidson, C T Ferrara-Cook, A Casagrande, A Krasner, 12531 Long-term Safety And Efficacy Of Once-daily Oral Paltusotine In The Treatment Of Patients With Acromegaly: Update From Acrobat Advance, Journal of the Endocrine Society, Volume 8, Issue Supplement_1, October-November 2024, bvae163.1269, https://doi.org/10.1210/jendso/bvae163.1269
Gadelha, M. R., Casagrande, A., Strasburger, C. J., Bidlingmaier, M., Snyder, P. J., Guitelman, M. A., Boguszewski, C. L., Buchfelder, M., Shimon, I., Raverot, G., Tóth, M., Mezősi, E., Doknic, M., Fan, X., Clemmons, D., Trainer, P. J., Struthers, R. S., Krasner, A., & Biller, B. M. K. (2024). Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine. The Journal of clinical endocrinology and metabolism, 110(1), 228–237. https://doi.org/10.1210/clinem/dgae385
Giustina, A., di Filippo, L., Uygur, M. M., & Frara, S. (2023). Modern approach to resistant acromegaly. Endocrine, 80(2), 303–307. https://doi.org/10.1007/s12020-023-03317-7
Giustina, A., Barkan, A., Beckers, A., Biermasz, N., Biller, B. M. K., Boguszewski, C., Bolanowski, M., Bonert, V., Bronstein, M. D., Casanueva, F. F., Clemmons, D., Colao, A., Ferone, D., Fleseriu, M., Frara, S., Gadelha, M. R., Ghigo, E., Gurnell, M., Heaney, A. P., Ho, K., … Melmed, S. (2020). A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. The Journal of clinical endocrinology and metabolism, 105(4), dgz096. https://doi.org/10.1210/clinem/dgz096
Holdaway, I. M., & Rajasoorya, C. (1999). Epidemiology of acromegaly. Pituitary, 2(1), 29–41. https://doi.org/10.1023/a:1009965803750
Kasuki, L., & Gadelha, M. R. (2022). Innovative therapeutics in acromegaly. Best practice & research. Clinical endocrinology & metabolism, 36(6), 101679. https://doi.org/10.1016/j.beem.2022.101679
Katznelson, L., Laws, E. R., Jr, Melmed, S., Molitch, M. E., Murad, M. H., Utz, A., Wass, J. A., & Endocrine Society (2014). Acromegaly: an endocrine society clinical practice guideline. The Journal of clinical endocrinology and metabolism, 99(11), 3933–3951. https://doi.org/10.1210/jc.2014-2700
Luo, R., Madan, A., Ferrara-Cook, C. T., Dalvie, D., Goulet, L., Struthers, R. S., & Krasner, A. S. (2025). Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants. British journal of clinical pharmacology, 91(7), 2070–2079. https://doi.org/10.1002/bcp.70020
Madan, A., Markison, S., Betz, S. F., Krasner, A., Luo, R., Jochelson, T., Lickliter, J., & Struthers, R. S. (2022). Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers. Pituitary, 25(2), 328–339. https://doi.org/10.1007/s11102-021-01201-z
Melmed S. (2009). Acromegaly pathogenesis and treatment. The Journal of clinical investigation, 119(11), 3189–3202. https://doi.org/10.1172/JCI39375
Melmed S. (2006). Medical progress: Acromegaly. The New England journal of medicine, 355(24), 2558–2573. https://doi.org/10.1056/NEJMra062453
Melmed, S., Colao, A., Barkan, A., Molitch, M., Grossman, A. B., Kleinberg, D., Clemmons, D., Chanson, P., Laws, E., Schlechte, J., Vance, M. L., Ho, K., Giustina, A., & Acromegaly Consensus Group (2009). Guidelines for acromegaly management: an update. The Journal of clinical endocrinology and metabolism, 94(5), 1509–1517. https://doi.org/10.1210/jc.2008-2421
Minniti, G., Jaffrain-Rea, M. L., Osti, M., Cantore, G., & Enrici, R. M. (2007). Radiotherapy for nonfunctioning pituitary adenomas: from conventional to modern stereotactic radiation techniques. Neurosurgical review, 30(3), 167–176. https://doi.org/10.1007/s10143-007-0072-x
Pirchio, R., Auriemma, R. S., Montini, M. E., Vergura, A., Pivonello, R., & Colao, A. (2023). Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience. Journal of endocrinological investigation, 46(5), 1027–1038. https://doi.org/10.1007/s40618-022-01980-7
Plöckinger, U., & Quabbe, H. J. (2005). Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta neurochirurgica, 147(5), 485–493. https://doi.org/10.1007/s00701-005-0511-9
Reid, T. J., Post, K. D., Bruce, J. N., Nabi Kanibir, M., Reyes-Vidal, C. M., & Freda, P. U. (2010). Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clinical endocrinology, 72(2), 203–208. https://doi.org/10.1111/j.1365-2265.2009.03626.x
Samson, S. L., Nachtigall, L. B., Fleseriu, M., Gordon, M. B., Bolanowski, M., Labadzhyan, A., Ur, E., Molitch, M., Ludlam, W. H., Patou, G., Haviv, A., Biermasz, N., Giustina, A., Trainer, P. J., Strasburger, C. J., Kennedy, L., & Melmed, S. (2020). Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. The Journal of clinical endocrinology and metabolism, 105(10), e3785–e3797. https://doi.org/10.1210/clinem/dgaa526
Wang, W., Yang, T., & Huang, Q. (2024). Quality of life in patients with acromegaly: a scoping review. Orphanet journal of rare diseases, 19(1), 251. https://doi.org/10.1186/s13023-024-03246-2
Webb, S. M., & Badia, X. (2016). Quality of Life in Acromegaly. Neuroendocrinology, 103(1), 106–111. https://doi.org/10.1159/000375451
Zhao, J., Wang, S., Markison, S., Kim, S. H., Han, S., Chen, M., Kusnetzow, A. K., Rico-Bautista, E., Johns, M., Luo, R., Struthers, R. S., Madan, A., Zhu, Y., & Betz, S. F. (2022). Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist. ACS medicinal chemistry letters, 14(1), 66–74. https://doi.org/10.1021/acsmedchemlett.2c00431
Views:
27
Downloads:
24
Copyright (c) 2026 Justyna Całka, Monika Kowalska, Katarzyna Ścibisz, Dominika Zdobylak, Karolina Ollik, Kamil Harenza, Anita Zięba, Michał Domin, Mateusz Taranowicz, Olga Kowalczyk
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
